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McIlvride S, Nikolova V, Fan HM, McDonald JA, Wahlström
A, Bellafante E, Jansen E, Adorini L, Shapiro D, Jones P,
Marchesi JR, Marschall HU, Williamson C. Obeticholic acid
ameliorates dyslipidemia but not glucose tolerance in mouse model
of gestational diabetes. Am J Physiol Endocrinol Metab 317:
E399 –E410, 2019. First published June 25, 2019; doi:10.1152/
ajpendo.00407.2018.—Metabolism alters markedly with advancing
gestation, characterized by progressive insulin resistance, dyslipide-
mia, and raised serum bile acids. The nuclear receptor farnesoid X
receptor (FXR) has an integral role in bile acid homeostasis and
modulates glucose and lipid metabolism. FXR is known to be func-
tionally suppressed in pregnancy. The FXR agonist, obeticholic acid
(OCA), improves insulin sensitivity in patients with type 2 diabetes
with nonalcoholic fatty liver disease. We therefore hypothesized that
OCA treatment during pregnancy could improve disease severity in a
mouse model of gestational diabetes mellitus (GDM). C57BL/6J mice
were fed a high-fat diet (HFD; 60% kcal from fat) for 4 wk before and
throughout pregnancy to induce GDM. The impact of the diet sup-
plemented with 0.03% OCA throughout pregnancy was studied.
Pregnant HFD-fed mice displayed insulin resistance and dyslipidemia.
OCA significantly reduced plasma cholesterol concentrations in non-
pregnant and pregnant HFD-fed mice (by 22.4%, P  0.05 and
36.4%, P  0.001, respectively) and reduced the impact of pregnancy
on insulin resistance but did not change glucose tolerance. In non-
pregnant HFD-fed mice, OCA ameliorated weight gain, reduced
mRNA expression of inflammatory markers in white adipose tissue,
and reduced plasma glucagon-like peptide 1 concentrations (by
62.7%, P  0.01). However, these effects were not evident in
pregnant mice. OCA administration can normalize plasma cholesterol
levels in a mouse model of GDM. However, the absence of several of
the effects of OCA in pregnant mice indicates that the agonistic action
of OCA is not sufficient to overcome many metabolic consequences
of the pregnancy-associated reduction in FXR activity.
bile acids; FXR; high-fat diet; insulin resistance
INTRODUCTION
Gestational diabetes mellitus (GDM) is increasingly preva-
lent worldwide in association with the rising incidence of
obesity in women of reproductive age (13, 17). Affected
women have increased risks of hypertensive disorders of preg-
nancy, including preeclampsia (52), and they have associated
dyslipidemia (48) in addition to hyperglycemia (48, 60). There
are also risks for the baby, including increased fetal growth that
can cause large-for-gestational-age infants and associated
shoulder dystocia, birth injury, and neonatal hypoglycemia (3,
7, 23, 45). Furthermore, GDM has long-term consequences for
both the mother and offspring, with increased risk of diabetes
and other morbidities associated with metabolic syndrome later
in life (6, 20).
The nuclear receptor farnesoid X receptor (FXR) not only
regulates bile acid homeostasis but also influences lipid and
glucose metabolism (27). FXR expression is reduced in rodent
models of both type 1 and type 2 diabetes mellitus (16), and
Fxr/ mice have elevated serum glucose concentrations and
insulin resistance (9, 32, 64), as well as hypercholanemia (37,
50). A recent study found that elevated total serum bile acids in
the first trimester of pregnancy was associated with increased
risk of developing GDM (25). Individual bile acid species also
differ between women with GDM and normal pregnancy (19).
Another study reported a strong inverse correlation between
taurine-conjugated bile acids and glycemic index that enabled
discrimination between GDM and uncomplicated pregnancy
(15). These changes in bile acid metabolism suggest that FXR
activity is altered in GDM. Indeed, one study has reported
reduced plasma levels of fibroblast growth factor (FGF) 19 in
GDM, which could be indicative of diminished intestinal FXR
activation (58). Furthermore, FXR activity is reduced in preg-
nancy (36), and women with gestational cholestasis have
increased rates of GDM (34, 61). We therefore hypothesized
that pharmacological activation of FXR could ameliorate the
insulin resistance and dyslipidemia that occurs in GDM.
Obeticholic acid (OCA) is a bile acid analog with markedly
higher affinity for FXR than the natural ligand, chenodeoxy-
cholic acid (47). OCA is approved for the treatment of primary
biliary cholangitis and is in phase 3 studies for the treatment of
nonalcoholic steatohepatitis, and clinical studies have shown
that OCA administration affects the lipid profile leading to
reduced plasma triglycerides (42, 57) and improves insulin
sensitivity (41). We hypothesized that OCA treatment could
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ameliorate impaired glucose tolerance, insulin resistance, and
dyslipidemia in a high-fat diet (HFD) mouse model of GDM.
MATERIALS AND METHODS
Animal studies. Six- to seven-week-old C57BL/6J mice were pur-
chased from Envigo (United Kingdom) and acclimatized to the animal
facility for 1 wk. Mice were maintained on a 12-h light-dark cycle
with free access to food and water. All experiments were performed
in accordance with the Animals (Scientific Procedures) Act 1986 and
approved by King’s College London’s Animal Welfare and Ethical
Review Body and the Home Office.
Female mice were fed standard CRM diet [normal chow (NC)] or
a high-fat diet (HFD; RM AFE 60% fat, cat. no. 824054, Special Diets
Services, UK), for 4 wk before being mated with age-matched male
mice (see Table 1 for diet composition). Upon identification of a
copulatory plug, considered to be day 1 of pregnancy (GD1), the
females either continued the same diet or received a diet supple-
mented with 0.03% OCA (~50 mg/kg per day). This dose was based
on a previous study of OCA administration in mice (4). A high dose
was chosen due to the short window of treatment allowed by preg-
nancy. Diet-matched virgin female mice (D0) were used as nonpreg-
nant controls and received OCA-supplemented diets for the same
period of time as pregnant mice. Mice were euthanized by CO2
inhalation on GD18 (or equivalent) after fasting for 4 h from 8 AM
and blood and tissues were collected.
Glucose and insulin tolerance tests. Glucose and insulin tolerance
tests were performed on GD16 or GD17, respectively. Mice were
fasted for 6 h from 8 AM and administered either 2 g/kg body weight
glucose or 0.75 IU/kg body weight insulin by intraperitoneal injection.
Blood glucose concentrations were measured using a FreeStyle Lite
glucometer (Abbott Healthcare, UK).
mRNA expression analysis. Total RNA was isolated from frozen
tissue samples using the RNeasy Mini Kit (Qiagen, UK) and reverse
transcribed using Superscript II Reverse Transcriptase (Thermo Fisher
Scientific, UK) according to the manufacturer’s instructions. Gene
expression was quantified by real-time PCR using SYBR Green
Mastermix (Sigma-Aldrich, UK) and a Viia7 system (Life Technol-
ogies, UK). Cyclophilin b was used as a housekeeping gene, and
relative expression of target genes was calculated by the Ct
method. The relative change in expression is given as 2-Ct. Primer
sequences are provided in Table 2.
Plasma glucagon-like peptide-1 measurement. Glucagon-like pep-
tide (GLP)-1 was measured in plasma samples taken from the portal
vein at euthanization on GD18 or equivalent by GLP-1 (Active)
ELISA (Millipore, UK) according to the manufacturer’s protocol.
Lipid biochemistry. Lipids were extracted from tissues in a 0.125 M
potassium phosphate buffer and normalized to total protein content.
Cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, free
fatty acids, and total protein were measured in plasma and tissue
extracts using a Unicel DxC 800 autoanalyzer (Beckman-Coulter, the
Netherlands) and dedicated kits, with the exception of free fatty acids,
which were measured using a kit from Wako Diagnostics (Germany).
Bile acid quantification. Bile acids were measured in plasma and
cecal samples collected at euthanization on GD18 or equivalent using
a high-performance liquid chromatography Alliance 2695 system
coupled to a Xevo TQ mass spectrometer using a SunFire C18 column
(4.6  100 mm, 3.5 m; Waters, UK), as previously described (49).
16S rRNA gene sequencing. DNA was extracted from cecal sam-
ples using the QIAamp Fast DNA Stool Mini Kit (QIAGEN, UK)
according to the manufacturers’ instructions. Sample libraries were
prepared as previously described (35). Sequencing was performed
using the MiSeq Reagent Kit v3 and paired-end 300 bp chemistry on
an Illumina Miseq platform (Illumina). Data analysis was performed
using Mothur software (v1.35.1; https://www.mothur.org/) following
Table 1. Diet composition
Composition [% (wt/wt)] CRM (Normal Chow) High-Fat Diet
Water 10.0 4.09
Crude protein 18.35 25.89
Vegetable-derived fat 3.36 4.87
Animal-derived fat 0.0 29.25
Crude fiber 4.23 4.98
Ash 6.27 4.8
Nitrogen-free extract 57.39 25.03
Energy
AFE (kcal AFE/g) 3.33 5.13
AFE from fat (% kcal) 9 60
AFE from protein (% kcal) 22 20
AFE from carbohydrate (% kcal) 69 20
AFE, Atwater fuel energy; CRM, standard diet.
Table 2. Primer sequences
Gene Forward Primer (5=-3=) Reverse Primer (3=-5=)
Abcg5 TCAATGAGTTTTACGGCCTGAA GCACATCGGGTGATTTAGCA
Abcg8 TGCCCACCTTCCACATGTC ATGAAGCCGGCAGTAAGGTAG
Asbt TCCTGGCTAGACTAGCTGGTC CTGAGTGTTCTGCATTCCAGTT
Bsep AAGCTACATCTGCCTTAGACAC CAATACAGGTCCGACCCTCTCT
Cd68 CCACAGGCAGCACAGTGGACA GCAGAAGCTTTGGCCCAAGGG
Cyp7a1 AGCAACTAAACAACCTGCCAGTACTA GTCCGGATATTCAAGGATGCA
Cyclophilin B TGGAGAGCACCAAGACAGACA TGCCGGAGTCGACAATGAT
Cyp8b1 TAGCCCTCTTTCCTCCACTCAT GAACCGATCGAACCTAAATTC
Fgf15 GAGGACCAAAACGAACGAAAT ACGTCCTTGATGGCAATCG
Fgfr4 CGCCAGCCTGCTACTATACAAA CCAGAGGACCTCGAGTCCAA
Hmgcr TTGGCACCATGTCAGGCGTCC AGCGACACACAGGCCGGGAA
Ibabp TGAGAGTGAGAAGAATTACGA TTACGTCCCCTTTCAATCACG
Ldlr CTGGTGACCGAAAACATCCAGT AATCAACCCAATAGAGACGGCC
Ntcp GAAGTCCAAAAGGCCACACTATTGT ACAGCCACAGAGAGGGAGAAAAG
Ost CTGAGCATAGTGGGCCCTGTTC AGCCTGGCGCTCTTCCTCAGAAATT
Ost TGACAAGCATGTTCCTCCTCAG TTCTTTGTCTTGTGCCTGCTTC
Shp CGATCCTCTTCAACCCAGATG AGGGCTCCAAGACTTCACACA
Srb1 GGGAGCGTGGACCCTATGT ACACGGTGTCGTTGTCATTGA
Srebp2 CCTAGACCTCGCCAAAGGTG AGGCTGTAGCGGATCACAT
Tnf AGCCCACGTCGTAGCAAACCA CCGTTGGCCAGGAGGGCGTT
-klotho GATGAAGAATTTCCTAAACCAGGTT AGCCTGGCGCTCTTCCTCAGAAATT
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the MiSeq SOP Pipeline (54). Sequence alignments were obtained
from the Silva bacterial database (https://www.arb-silva.de/), and
sequences were classified according to the Ribosomal Database Proj-
ect reference sequence files using the Wang method (18). Nonmetric
multidimensional scaling plots and permutational multivariate analy-
sis of variance P values were produced using the UniFrac weighted
distance matrix created by Mothur, and analysis was carried out using
the Vegan library (5) within the statistical software, R (www.r-
project.org). Bacterial relative abundance was expressed as extended
error bar plots using the Statistical Analysis of Metagenomic Profiles
software package using White’s nonparametric t-test with Benjamini-
Hochberg false discovery rate. P and q values 0.05 were considered
significant.
Statistical analysis. Data are expressed as means  SE. Statistical
analysis was performed using GraphPad Prism software (version 7;
GraphPad Software), unless otherwise specified. Data were assessed
for normality using the Shapiro-Wilk normality test. Where two
groups were being compared, Student’s t-test was used. For compar-
ison of three or more groups, ANOVA was used, followed by Tukey’s
post hoc analysis, unless otherwise specified. A P value  0.05 was
considered significant.
RESULTS
OCA ameliorates weight gain and white adipose tissue
inflammation in nonpregnant HFD-fed mice. Nonpregnant
mice that were treated with OCA gained significantly less
weight than mice fed HFD alone; however, no difference was
observed in pregnant mice (Fig. 1A). This difference was also
evident when maternal weight was normalized by subtracting
the weight of the uterine horn and contents at GD18 (Fig. 1B).
The liver-to-body weight ratio was significantly reduced by
HFD feeding in nonpregnant mice only, which was also less-
ened by OCA treatment (Fig. 1C). OCA also significantly
reduced the expression of inflammatory markers Cd68 and
Tnf- in white adipose tissue of nonpregnant HFD-fed mice
(Fig. 1D).
OCA does not improve glucose tolerance in HFD-fed mice.
Glucose and insulin tolerance tests were performed on GD16
or GD17, respectively, or equivalent for nonpregnant controls.
Both nonpregnant and pregnant mice displayed significantly
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Fig. 1. Obeticholic acid (OCA) ameliorates weight gain and white adipose tissue inflammation in nonpregnant high-fat diet (HFD)-fed mice. A: weight gain in
nonpregnant (D0) and pregnant (D18) mice before and after HFD prefeeding and at gestational days (GD) 7, 14, and 18. P  0.05 as determined by two-way
ANOVA followed by Tukey’s multiple comparisons test for the following comparisons: b, normal chow (NC) vs. HFD; c, HFD vs. HFD OCA. B: body weight
(BW) at GD18, without uterine horn. C: liver weight at GD18 normalized to BW without uterine horn. D: relative mRNA expression of inflammatory markers
in gonadal white adipose tissue at GD18. *P 0.05 vs. NC control, #P 0.05 vs. HFD control as determined by one-way ANOVA followed by Tukey’s multiple
comparisons test. Data are expressed as means  SE; n 	 5–11 mice per group.
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impaired glucose tolerance upon HFD feeding (Fig. 2A), but
only pregnant HFD-fed mice had significantly reduced insulin
tolerance (Fig. 2B). There was no effect of OCA treatment on
glucose tolerance. Insulin tolerance was improved by OCA in
pregnant HFD-fed mice, but it did not return to baseline levels.
OCA significantly reduced fasted plasma GLP-1 levels in NC-
and HFD-fed nonpregnant mice, but not in pregnant mice
(Fig. 2C).
OCA reduces plasma cholesterol in nonpregnant and preg-
nant mice. HFD feeding caused a significant increase in total
plasma cholesterol in pregnant mice only. However, OCA
administration significantly reduced the total cholesterol in
HFD-fed nonpregnant mice (Fig. 3A). In pregnant mice,
OCA treatment significantly reduced total cholesterol in
both NC- and HFD-fed mice (Fig. 3A). This effect was
largely due to a reduction in HDL cholesterol, although
OCA also significantly reduced LDL cholesterol in HFD-fed
pregnant mice (Fig. 3, B and C). There was no effect of
OCA on plasma triglyceride or free fatty acid levels (data
not shown), and hepatic lipid levels were also unaffected by
OCA treatment (data not shown). When expression of lipid
homeostasis targets was assayed in maternal liver, the anal-
ysis showed that in NC-fed mice OCA significantly reduced
the expression of targets, including Srebp2, a transcription
factor regulating cholesterol synthesis; Abcg5/8, which ef-
fluxes sterols (including cholesterol) into bile; and the LDL
and HDL receptors, Ldlr and Srb1. Expression of Hmgcr,
the rate-limiting enzyme in cholesterol synthesis, was un-
changed by OCA treatment. However, these effects were not
apparent in pregnant mice (Fig. 3E), despite them also
having reduced plasma cholesterol. This observation led us
to conclude that either the reduction in cholesterol is not due
to any transcriptional changes in hepatic lipid homeostasis
pathways or the mechanisms are distinct in nonpregnant and
pregnant mice. Consistent with previous studies (43),
mRNA expression of cholesterol homeostasis targets is
reduced in late pregnancy in mice (Fig. 3D). Furthermore,
HFD feeding also reduced expression of these targets, with
no further effect of OCA with the exception of increased
Srebp2 expression in HFD-fed nonpregnant mice. This sug-
gests that the repression of these targets by pregnancy and
HFD has abrogated any impact of OCA. There was no effect
of OCA on lipid biochemistry in the placenta or fetal liver
(data not shown).
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Fig. 2. Obeticholic acid (OCA) does not improve glucose tolerance in high-fat diet (HFD)-fed mice. A: glucose tolerance tests (GTT) were performed on day
16 of pregnancy [or equivalent for nonpregnant (D0) controls]; n	 7–10 mice per group. B: insulin tolerance tests (ITT) were performed on day 17 of pregnancy
(or equivalent for D0 controls); n 	 7–11 mice per group. P  0.05 as determined by two-way repeated measures ANOVA followed by Tukey’s multiple
comparisons test; a, normal chow (NC) vs. NC OCA; b, NC vs. HFD. For area under the curve (AUC), *P  0.05 vs. NC, as determined by one-way ANOVA
followed by Tukey’s multiple comparisons test. C: glucagon-like peptide 1 (GLP-1) concentrations were measured in plasma collected from the portal vein upon
euthanization at gestational day 18 (D18) (or equivalent for D0 controls). *P  0.05 vs. NC, #P  0.05 vs. HFD, as determined by one-way ANOVA followed
by Tukey’s multiple comparisons test; n 	 6–8 mice per group. Data are expressed as means  SE.
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OCA modulates plasma bile acids in NC- but not HFD-fed
mice. Because of the key role of FXR in modulating bile acid
homeostasis, bile acid concentrations were measured in mater-
nal plasma. There was no significant effect of HFD or OCA on
either total plasma bile acids or total unconjugated and conju-
gated bile acids (Fig. 4, A–C). HFD did not significantly impact
individual bile acid species concentrations (Fig. 4, D and E). In
nonpregnant NC-fed mice, OCA caused an increase in 
- and
-muricholic acid (MCA), chenodeoxycholic acid (CDCA),
and ursodeoxycholic acid (UDCA) and a decrease in deoxy-
cholic acid (DCA). OCA did not alter any bile acid species in
HFD-fed nonpregnant mice. In pregnancy, OCA treatment
similarly caused a significant increase in UDCA and decrease
in DCA and also caused a decrease in taurocholic acid (TCA)
in NC-fed mice. However, in HFD-fed mice, OCA decreased
DCA concentrations only. Of note, OCA and tauro-OCA were
both present in plasma at similar levels across all groups fed
OCA, confirming absorption of OCA from the diet.
OCA affects cecal bile acids disparately in pregnant and
nonpregnant mice. Bile acids were also measured in the cecum,
which reflects the bile acid composition of the colon and feces
(49). Total cecal bile acid concentrations were not different
between any of the groups (Fig. 5A). However, HFD and OCA
affected total primary and secondary bile acids disparately in
nonpregnant and pregnant mice (Fig. 5, B and C). HFD feeding
caused an increase in the total concentration of primary bile
acids in D18 mice and also elevated total secondary bile acids
in D0 mice. OCA caused an increase in total primary bile acids
in HFD-fed D0 mice, predominantly due to raised conjugated
and unconjugated MCA (Fig. 5, D and E). However, in
pregnant mice, OCA reduced total secondary bile acids in
NC-fed D18 mice, largely due to reduced DCA and MCA
(Fig. 5D). As expected, cecal bile acids were predominantly
unconjugated (Fig. 5, D and E).
OCA alters cecal microbiome in NC- but not HFD-fed mice.
Because of the relationship between bile acids and the intesti-
nal microbiome (56), 16S rRNA genes were sequenced to
characterize the cecal microbiota. Distribution of cecal micro-
biota was most affected by HFD feeding (Fig. 6A), with
alterations in Bacteroidetes, Proteobacteria, and Deferribacte-
res in particular. Similarly, this is reflected in nonmetric
multidimensional scaling plots showing that the composition
of cecal microbiota is markedly different in HFD-fed mice
compared with NC-fed mice (Fig. 6, B and C). However, no
effect of OCA was observed on bacterial taxa in the HFD
groups (data not shown). In NC-fed nonpregnant mice, how-
ever, OCA treatment led to distinct differences in microbiota
(Fig. 6B). Furthermore, OCA had a greater impact on relative
abundance of bacterial families in nonpregnant mice compared
with pregnant mice (Fig. 6C). In particular, OCA treatment
caused a large increase in an unclassified Bacteroidales family
and a decrease in the Firmicutes family Ruminococcaceae.
Both pregnancy and HFD alter OCA’s impact on FXR
signaling. Our data show that several effects of OCA in
nonpregnant mice are absent in pregnant mice. Gene expres-
sion of FXR targets was therefore examined in the liver and
distal ileum. Confirming previous studies from our group (36,
44) and others (40), expression of FXR targets in the liver and
distal ileum is reduced in pregnancy (Fig. 7, A and C). OCA
treatment caused induction of Bsep and reduction of Cyp8b1,
Ntcp, Fgfr4, and -klotho in the livers of nonpregnant NC-fed
mice (Fig. 7B). In pregnant mice, there was induction of Shp
and reduction of Cyp7a1 and Cyp8b1. In the ileum, OCA
increased Shp, Fgf15, and Ibabp in nonpregnant NC-fed mice,
but only Fgf15 was significantly altered in pregnant NC-fed
mice (Fig. 7D). OCA treatment in HFD-fed mice had minimal
impact on gene expression in the liver, with only Bsep in-
creased in nonpregnant mice (Fig. 7B). In the ileum, Shp,
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Ibabp, and Ost/ were all induced by OCA in nonpregnant
mice, but only Ost/ was increased in pregnant HFD-fed
mice (Fig. 7D).
DISCUSSION
Our data show that OCA improves dyslipidemia and insulin
resistance but has no impact on impaired glucose tolerance in
a mouse model of GDM. Many of the effects of OCA that were
observed in nonpregnant mice were not seen in pregnancy,
consistent with the known reduction in FXR activity in preg-
nancy (36); thus, the efficacy of OCA was limited.
To induce features of gestational diabetes, mice were fed a
high-fat diet (HFD) for 4 wk before and during pregnancy.
This model has previously been used to induce features of
GDM in mice, such as insulin resistance and dyslipidemia (24,
26, 31). A period of only 4 wk of HFD exposure before
pregnancy is not sufficient to cause a diabetic phenotype;
however, continued feeding throughout pregnancy leads to
progressive glucose intolerance and insulin resistance, mim-
icking human disease. In our model, the mice receiving a HFD
were significantly glucose intolerant but only demonstrated
significant insulin resistance when coupled with pregnancy.
This difference could explain why OCA had no effect on
insulin sensitivity in nonpregnant animals, in contrast to pre-
vious animal and human studies (41, 55). Alternatively, it
could be due to the duration of OCA treatment, which is
limited in our model by the 19–21 day gestation length in
mice. Although insulin resistance was lessened in pregnant
HFD-fed OCA mice, there was no effect of OCA on glucose
tolerance. Furthermore, OCA treatment reduced fasting plasma
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GLP-1 in both NC- and HFD-fed nonpregnant mice. The
involvement of FXR in GLP-1 secretion is unclear, with
reports of FXR activation both increasing and inhibiting GLP-1
secretion (46, 53). Nevertheless, this effect was not apparent in
pregnant mice, suggesting that OCA interacts differently with
FXR in pregnancy.
OCA did consistently impact plasma cholesterol levels, as
total cholesterol was significantly decreased in nonpregnant
HFD-fed mice and pregnant NC- and HFD-fed mice treated
with OCA. This change was due to decreased HDL and LDL
cholesterol in pregnant HFD-fed mice. This finding has previ-
ously been observed in nonpregnant animals (14, 62) and has
been suggested to be due to increased reverse cholesterol
transport. Xu et al. (62) observed increased fecal cholesterol
and reduced fecal bile acids, whereas Dong and colleagues (14)
observed increased mRNA and protein expression of hepatic
scavenger receptor class B type 1 (SR-B1) accompanied by
increased fecal cholesterol. Fecal cholesterol concentrations
were not measured in this study. However, we did not observe
any changes in fecal bile acids with OCA treatment. Interest-
ingly, our data show that hepatic Srb1 expression was reduced
in nonpregnant NC-fed mice treated with OCA, a group with
no changes in plasma cholesterol, but it was not altered in
pregnant animals and there was no impact of OCA treatment in
HFD-fed mice.
OCA significantly reduced weight gain at D14 in nonpreg-
nant HFD-fed mice, as has been observed previously (22). This
effect was not apparent in pregnant animals and is likely due to
the gestational changes that impact maternal morphometry,
such as hyperphagia and promotion of storage of energy in
white adipose tissue, which have a greater impact on body
weight than HFD. HFD is commonly used to induce maternal
obesity in rodents, but the prepregnancy exposure period is
typically longer than 4 wk (21, 26, 28, 30). Adipose depot mass
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was not measured in our study; therefore, it is possible that
OCA may have caused differences without affecting total body
weight, as has been observed in HFD-fed rabbits treated with
OCA (33). As well as reducing weight gain, OCA also reduced
mRNA expression of inflammatory markers in white adipose
tissue of HFD-fed nonpregnant mice. FXR has been shown to
regulate inflammatory responses via nuclear factor B (59),
and OCA has previously been shown to reduce expression of
inflammatory markers in adipose tissue (22). Notably, this
effect was not observed in pregnant mice. It is known that
expression of proinflammatory adipokines is increased in white
adipose tissue in rodent pregnancy (8, 10, 63); therefore, it is
possible that the gestational signals that mediate this proinflam-
matory profile are not overcome by FXR activation by OCA.
OCA also impacted cecal bile acids differently in pregnant
and nonpregnant mice. In plasma, the effect of OCA on
individual bile acids generally followed the same pattern in
pregnant and nonpregnant mice, whereas in the cecum OCA
caused a significant increase in the total concentration of
primary bile acids in nonpregnant HFD-fed OCA mice. In
pregnancy, however, OCA caused a significant decrease in the
total concentration of secondary bile acids in NC-fed OCA
mice. There is a trend for primary bile acids to also be reduced
in the cecum from this group, as well as increased plasma
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unconjugated bile acids, which could suggest increased absorp-
tion of bile acids in the ileum.
Because of the alterations in cecal bile acid concentrations,
we investigated whether OCA-treated mice had altered micro-
biota in the cecum. Feeding mice HFD caused the most marked
changes in the cecal microbiota, which could potentially mask
any effect of OCA treatment in these groups. OCA treatment of
NC-fed mice also caused significant differences in microbiota
that were not observed in pregnant mice, such as significantly
reduced Ruminococcaceae, which are a family of Firmicutes
bacteria, and a significant increase in an unclassified family of
the Bacteroidetes phylum. This is consistent with a recent
study from our group showing that mice fed CA, an FXR
ligand albeit significantly less potent than OCA, have an
increased ratio of Bacteroidetes to Firmicutes accompanied by
enhanced enterohepatic feedback via Fgf15 (44). These large
changes were absent in pregnant mice, highlighting the differ-
ent effect of OCA on the microbiome in pregnant and non-
pregnant mice. However, it was surprising that there were not
more differences between microbiota of nonpregnant and preg-
nant control mice, which is in contrast to our recent study that
found that pregnancy, as well as CA feeding, is associated with
an increased ratio of Bacteroidetes to Firmicutes. We observed
a small trend for an increased Bacteroidetes-to-Firmicutes
ratio, but it did not reach significance. This may be explained
by the fact that the Ovadia study (44) used whole shotgun
genome metagenomic sequencing; additionally, the mice were
bred and housed differently and received a different control
diet (RM3).
Several of the effects of OCA described herein were not
evident in pregnant mice. The similar plasma and cecal levels
of OCA and tauro-OCA across all of the groups suggest that
this is not due to differences in OCA intake or absorption. A
potential explanation for the absence of OCA-related effects in
pregnancy could have been higher circulating amounts of FXR
antagonistic bile acids, such as taurine-conjugated 
/-MCA
(49); however, our serum data do not support this explanation.
Hepatic FXR activity is known to be reduced in pregnancy (36)
due to the effects of reproductive hormones including proges-
terone sulphates (1) and 17-estradiol (51). Ileal expression of
FXR targets is also known to be reduced in pregnancy (39, 44).
Therefore, it is plausible that activation of FXR by OCA is
diminished in pregnancy, and this decreased activation is why
effects such as decreased white adipose tissue inflammation
and reduced GLP-1 secretion are not seen. It should also be
noted that induction of FXR targets by OCA differed between
NC- and HFD-fed pregnant mice; in particular, there was no
increase in ileal Fgf15 and corresponding decrease in Cyp7a1
in the liver of HFD-fed OCA pregnant mice. It has been
observed previously in male C57BL/6 mice that Fgf15 expres-
sion was decreased in the distal ileum after 4–8 wk of HFD
(12), and decreased circulating FGF19 has been reported in
human obese subjects (2). We observed no impact of HFD
alone on FXR targets in the ileum; nevertheless, it is possible
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that HFD has an independent effect on enterohepatic feedback
via FGF15 that should be taken into consideration. Despite
these differences, the effect of OCA on plasma cholesterol is
consistent between nonpregnant and pregnant mice and was
also evident in HFD-fed mice. The mechanism for the reduc-
tion in plasma cholesterol is unclear, as expression of genes
involved in hepatic lipid homeostasis was unchanged by OCA
treatment in pregnant mice; therefore, future studies are
needed.
A limitation of this study is the relatively mild disease
phenotype induced by the HFD. Although pregnant HFD-fed
mice were significantly insulin resistant compared with preg-
nant NC-fed mice, fasting glucose and plasma triglyceride
levels were normal. We were unable to monitor food intake
due to the consistency of the HFD, and a recent study has
shown that consumption of HFD can vary substantially in
C57BL/6J mice (11). It would therefore be of interest to also
study a genetic model of GDM, such as the heterozygous leptin
receptor deficient (Lepr(db/)) mouse (29). Although we can-
not be certain that food intake was similar between groups, it
is known that OCA supplementation of HFD did not affect
food intake in transgenic mice bred on a C57BL/6J background
(38). Another limitation of using HFD is that it is manufactured
with purified ingredients, unlike the control NC. Although we
are not specifically interested in the effects of OCA on a HFD
in pregnancy but rather the disease features it induces, it could
be a confounding factor to take into consideration.
In conclusion, OCA does not improve glucose tolerance in a
HFD model of GDM. However, OCA treatment significantly
improved maternal hypercholesterolemia. It is likely that FXR
activation by OCA is blunted in pregnant mice due to the
gestational suppression of FXR activity. Therefore, gestational
suppression of FXR activity should be taken into account when
considering FXR agonists as a treatment for metabolic disor-
ders in pregnancy.
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